****
69th Legislature 2025 LC 2725
1 _____________ BILL NO. _____________
2 INTRODUCED BY _________________________________________________
(Primary Sponsor)
3
4 A BILL FOR AN ACT ENTITLED: “AN ACT REVISING THE RIGHT TO TRY ACT; LIMITING THE
5 TREATMENT OF MINORS WHO HAVE A TERMINAL ILLNESS WITH AN INVESTIGATIONAL DRUG,
6 BIOLOGICAL PRODUCT, OR DEVICE; AND AMENDING SECTION 50-12-104, MCA.”
7
8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
9
10 Section 1. Section 50-12-104, MCA, is amended to read:
11 "50-12-104. Patient requirements. (1) A patient is eligible for treatment with an investigational drug,
12 biological product, or device if the patient has:
13 (1) (a) considered all other treatment options currently approved by the United States food and drug
14 administration;
15 (2) (b) received a recommendation from the patient's treating health care provider for an
16 investigational drug, biological product, or device;
17 (3) (c) given written informed consent for the use of the investigational drug, biological product, or
18 device; and
19 (4) (d) documentation from the treating health care provider that the patient meets the requirements of
20 this section.
21 (2) A minor is not eligible for treatment with an investigational drug, biological product, or device
22 unless the minor has a terminal illness that is attested to by the minor's treating health care provider."
23 - END -
- 1 - LC 2725

[DELETED:  L- _IATBB0S1" P2b3()c4a5()r6i7()g8d9()d0t1()A2u3-]